143 related articles for article (PubMed ID: 16566722)
1. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model.
Ferrario A; Gomer CJ
J Environ Pathol Toxicol Oncol; 2006; 25(1-2):251-9. PubMed ID: 16566722
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.
Ferrario A; von Tiehl KF; Rucker N; Schwarz MA; Gill PS; Gomer CJ
Cancer Res; 2000 Aug; 60(15):4066-9. PubMed ID: 10945611
[TBL] [Abstract][Full Text] [Related]
4. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins.
Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
Photochem Photobiol Sci; 2007 Dec; 6(12):1275-83. PubMed ID: 18046482
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Ferrario A; Fisher AM; Rucker N; Gomer CJ
Cancer Res; 2005 Oct; 65(20):9473-8. PubMed ID: 16230411
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of hypericin-mediated photodynamic therapy in combination with angiogenesis inhibitor bevacizumab using in vivo fluorescence confocal endomicroscopy.
Bhuvaneswari R; Thong PS; Gan YY; Soo KC; Olivo M
J Biomed Opt; 2010; 15(1):011114. PubMed ID: 20210440
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer.
Peng CL; Lin HC; Chiang WL; Shih YH; Chiang PF; Luo TY; Cheng CC; Shieh MJ
Photodiagnosis Photodyn Ther; 2018 Sep; 23():111-118. PubMed ID: 29894822
[TBL] [Abstract][Full Text] [Related]
8. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
[TBL] [Abstract][Full Text] [Related]
10. Effect of hypericin-mediated photodynamic therapy on the expression of vascular endothelial growth factor in human nasopharyngeal carcinoma.
Bhuvaneswari R; Gan YY; Yee KK; Soo KC; Olivo M
Int J Mol Med; 2007 Oct; 20(4):421-8. PubMed ID: 17786271
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy: combined modality approaches targeting the tumor microenvironment.
Gomer CJ; Ferrario A; Luna M; Rucker N; Wong S
Lasers Surg Med; 2006 Jun; 38(5):516-21. PubMed ID: 16607618
[TBL] [Abstract][Full Text] [Related]
12. Pro-apoptotic and anti-inflammatory properties of the green tea constituent epigallocatechin gallate increase photodynamic therapy responsiveness.
Ferrario A; Luna M; Rucker N; Wong S; Gomer CJ
Lasers Surg Med; 2011 Sep; 43(7):644-50. PubMed ID: 22057492
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer.
Solban N; Selbo PK; Sinha AK; Chang SK; Hasan T
Cancer Res; 2006 Jun; 66(11):5633-40. PubMed ID: 16740700
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Zhou Q; Olivo M; Lye KY; Moore S; Sharma A; Chowbay B
Cancer Chemother Pharmacol; 2005 Dec; 56(6):569-77. PubMed ID: 16001166
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine.
Albini A; Morini M; D'Agostini F; Ferrari N; Campelli F; Arena G; Noonan DM; Pesce C; De Flora S
Cancer Res; 2001 Nov; 61(22):8171-8. PubMed ID: 11719447
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.
Jia Z; Zhang J; Wei D; Wang L; Yuan P; Le X; Li Q; Yao J; Xie K
Cancer Res; 2007 May; 67(10):4878-85. PubMed ID: 17510417
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Kaposi's sarcoma in vivo by fenretinide.
Ferrari N; Morini M; Pfeffer U; Minghelli S; Noonan DM; Albini A
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6020-9. PubMed ID: 14676128
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
20. Lipoxins exert antiangiogenic and anti-inflammatory effects on Kaposi's sarcoma cells.
Marginean A; Sharma-Walia N
Transl Res; 2015 Aug; 166(2):111-33. PubMed ID: 25814167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
